Kenji Fukutome1*†
Mikio Shiba2†
Shuta Aketa1Takaaki Mitsui1Yuki Shiraishi1
Hiromichi Hayami1Yasutaka Murakami3Ryuta Matsuoka1Rinsei Tei1Yasushi Shin1Yasushi Motoyama1- 1Department of Neurosurgery, Osaka Police Hospital, Osaka, Japan
- 2Cardiovascular Division, Osaka Police Hospital, Osaka, Japan
- 3Department of Neurology, Osaka Police Hospital, Osaka, Japan
We report a case in which neointima was confirmed by angioscopy and antiplatelet drug administration was reduced 2 months after carotid artery stenting (CAS). A patient in their 80s was scheduled to undergo resection for renal cancer; however, he also had right cervical internal carotid artery stenosis. Because this was a risk for general anesthesia, CAS was performed after first starting dual antiplatelet therapy. Urologically, early reduction of antiplatelet drugs was necessary for a nephrectomy. Although no obvious neointima could be identified on ultrasound 2 months after CAS, thin neointima was observed using angioscopy. Based on the above results, we reduced the antiplatelet drug administration, and then the nephrectomy was performed. Ultimately, no cerebral infarction occurred in the perioperative or postoperative periods. Angioscopy allows for visual confirmation of thin neointima. If sufficient neointima can be confirmed, antiplatelet drug reduction can be performed more safely and reliably.
Introduction
Before carotid artery stenting (CAS), dual antiplatelet treatment (DAPT) is necessary to prevent thrombosis (1–4). Long-term DAPT carries the risk of bleeding problems; thus, it is preferable to reduce the dose as soon as possible (3, 4). However, it is unclear how long it should be continued following CAS. If the struts of the stent are suitably coated with neointima, the risk of thrombosis is decreased, and antiplatelet medications may be stopped early. However, because early neointima is thin, it can be challenging to detect using carotid ultrasonography (CUS) or angiography. In this work, we describe a case in which CUS was unable to identify the neointima, but macroscopic inspection using angioscopy could detect the presence of a thin neointima, thereby allowing for a reduction in antiplatelet medication 2 months after CAS.
Case report
A patient in their 80s was scheduled to undergo resection for renal cancer, but he was referred to our department because right cervical internal carotid artery stenosis was suddenly discovered when using CUS for screening before general anesthesia. Right common carotid artery angiography revealed 82% stenosis (North American Symptomatic Carotid Endarterectomy Trial method), even though it was asymptomatic (Figures 1A,B); therefore, after beginning DAPT (aspirin and clopidogrel), CAS utilizing CASPER Rx (Terumo, Tokyo, Japan) was conducted (Figures 1C,D). In terms of urology, an early nephrectomy was required along with a reduction in antiplatelet medication.
Figure 1. (A,B) Right internal carotid artery origin was 82% stenosed (North American Symptomatic Carotid Endarterectomy Trial method) according to the results of right common carotid artery angiography (ICA). (C,D) CASPER Rx was placed at the right ICA; the blood flow improved. [(A,C), anteroposterior view; (B,D), lateral view].
Two months after CAS, another workup with angiography and angioscopy was conducted because it was challenging to detect the neointima within the stent using CUS (Figure 2A). After systemic heparinization, right common carotid angiography showed a radiolucent gap between the stent and lumen of the artery, suggesting neointimal formation (Figure 2B). After that, thin neointimal development was observed throughout the stent, except for the external carotid artery orifice, where the lumen was visually inspected with an angioscope VISIBLE (Intertec Medicals, Osaka, Japan) under proximal blood flow obstruction with a balloon catheter (Figure 2C). The obstruction time was less than 1 min and there were no ischemic symptoms.
Figure 2. (A) Using ultrasonography, neointimal formation in CASPER Rx could not be detected (white arrowheads: CASPER Rx). (B) A radiolucent gap between the stent and artery lumen was discovered during right common carotid angiography. (C) Using angioscopy, thin neointimal development was seen throughout, except for the external carotid artery orifice (black arrowheads: the orifice of the external carotid artery).
Based on the above findings, we determined that the risk of thrombosis was low, decreased the antiplatelet drug administration to one (only aspirin), and then conducted the nephrectomy at the department of urology. In the end, there was no perioperative or postoperative cerebral infarction.
Discussion
Although there are accounts of angioscopy evaluations of plaque before and after (5–7), there are no reports of angiography evaluations of neointima sometime after CAS. In this report, CUS was conducted 2 months after CAS, but no neointima could be identified. However, investigations on coronary arteries have indicated that neointima are typically seen 1–1.5 months following the implantation of a bare-metal stent (8). Although it is challenging to decide whether or not to reduce the antiplatelet drug administration based on the findings of CUS alone, direct confirmation of the neointima by angioscopy may allow a safer and more reliable decision to reduce the dose. Other intravascular ultrasound devices exist, such as intravascular ultrasound and optical coherence tomography; however, similar to CUS, identification is problematic if the neointima is thin. In general, neointima may be formed more or less 2 months after CAS, and it is possible that antiplatelet medication can be lowered or stopped at this point. The timing of neointima development may vary if a stent with a different shape, such as a single layer, is employed over a dual layer stent, such as the one used in this study. On the one hand, a dual layer is less likely to form neointima because of the increased amount of metal; on the other hand, it is more likely to form neointima because of the increased scaffolding.
A drawback of an angioscope is that, depending on the blood vessel’s diameter, it is rigid and has a narrow field of vision, making it challenging to thoroughly inspect the interior of a stent. It is a somewhat more intrusive test than conventional angiography because proximal blood flow blockage is required to provide a decent viewing field.
Conclusion
Thin neointima that is not visible under CUS can be visually confirmed using angioscopy. Antiplatelet drug lowering can be conducted more securely and consistently if enough neointima can be verified. Antiplatelet medication may typically be lowered or stopped at that point because in-stent neointima formation is complete 2 months after CAS.
Data availability statement
The original contributions presented in the study are included in the article/Supplementary material, further inquiries can be directed to the corresponding author.
Ethics statement
The studies involving human participants were reviewed and approved by Osaka Police Hospital. The patients/participants provided their written informed consent to participate in this study. Written informed consent was obtained from the participant/patient(s) for the publication of this case report.
Author contributions
KF, MS, SA, TM, YuS, HH, YMu, RM, RT, YaS, and YMo contributed to the work described in this paper, involved in the clinical management of the patient, and revised the manuscript. KF and MS conceived and designed the experiment, and drafted the manuscript. SA and YM supervised and coordinated the study and the manuscript. All authors contributed to the article and approved the submitted version.
Acknowledgments
The authors thank Atsushi Hirayama and Yoshiharu Higuchi for their interpretation of the angioscopic imaging.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Supplementary material
The Supplementary material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fneur.2023.1152173/full#supplementary-material
References
1. American College of Cardiology Foundation, American Society of Interventional & Therapeutic Neuroradiology, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional RadiologyBates, ER, et al. ACCF/SCAI/SVMB/SIR/ASITN 2007 clinical expert consensus document on carotid stenting: a report of the American College of Cardiology Foundation task force on clinical expert consensus documents (ACCF/SCAI/SVMB/SIR/ASITN clinical expert consensus document committee on carotid stenting). J Am Coll Cardiol. (2007) 49:126–70. doi: 10.1016/j.jacc.2006.10.021
2. Dalainas, I, Nano, G, Bianchi, P, Stegher, S, Malacrida, G, and Tealdi, DG. Dual antiplatelet regime versus acetyl-acetic acid for carotid artery stenting. Cardiovasc Intervent Radiol. (2006) 29:519–21. doi: 10.1007/s00270-005-5288-y
3. McKevitt, FM, Randall, MS, Cleveland, TJ, Gaines, PA, Tan, KT, and Venables, GS. The benefits of combined anti-platelet treatment in carotid artery stenting. Eur J Vasc Endovasc Surg. (2005) 29:522–7. doi: 10.1016/j.ejvs.2005.01.012
4. Sussman, ES, Jin, M, Pendharkar, AV, Pulli, B, Feng, A, Heit, JJ, et al. Dual antiplatelet therapy after carotid artery stenting: trends and outcomes in a large national database. J Neurointerv Surg. (2021) 13:8–13. doi: 10.1136/neurintsurg-2020-016008
5. Enomoto, Y, Egashira, Y, Funatsu, N, Yamauchi, K, Matsubara, H, and Iwama, T. The effect of stent design on plaque protrusion after carotid artery stenting. J Neuroendovasc Ther. (2022) 16:237–42. doi: 10.5797/jnet.oa.2021-0066
6. Enomoto, Y, Egashira, Y, and Iwama, T. What's happening in carotid stent? A case report of prominent plaque protrusion after carotid artery stenting observed on angioscopy. Catheter Cardiovasc Interv. (2021) 97:E532–5. doi: 10.1002/ccd.29186
7. Kondo, H, Kiura, Y, Takeshita, S, Magaki, T, Sakoguchi, T, Mukai, T, et al. Angioscopic findings in 3 patients who required retreatment after carotid artery stenting. World Neurosurg. (2019) 130:358–63. doi: 10.1016/j.wneu.2019.06.191
Keywords: angioscopy, angiography, carotid artery stenting, dual antiplatelet therapy, neointima
Citation: Fukutome K, Shiba M, Aketa S, Mitsui T, Shiraishi Y, Hayami H, Murakami Y, Matsuoka R, Tei R, Shin Y and Motoyama Y (2023) Case report: Usefulness of angioscopy in determining antiplatelet drug reduction after carotid artery stenting. Front. Neurol. 14:1152173. doi: 10.3389/fneur.2023.1152173
Edited by:
Anna Bersano, IRCCS Carlo Besta Neurological Institute Foundation, ItalyReviewed by:
Alberto Maud, Texas Tech University Health Sciences Center El Paso, United StatesChingiz Nurimanov, National Center for Neurosurgery, Kazakhstan
Salvatore D’Amato, University of Texas Health Science Center at Houston, United States
Copyright © 2023 Fukutome, Shiba, Aketa, Mitsui, Shiraishi, Hayami, Murakami, Matsuoka, Tei, Shin and Motoyama. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Kenji Fukutome, a2VuamlmdWt1dG9tZTgyQGdtYWlsLmNvbQ==
†These authors have contributed equally to this work